IGM Biosciences Faces Nasdaq Non-Compliance Notice

IGM Biosciences ( (IGMS) ) has issued an update.

On June 6, 2025, IGM Biosciences received a notice from Nasdaq indicating non-compliance with the minimum Market Value of Listed Securities requirement of $50 million. The company has until December 3, 2025, to regain compliance, failing which it may face delisting. IGM Biosciences plans to monitor its market value closely and explore options to meet the compliance requirements, including the possibility of transferring its stock listing to The Nasdaq Capital Market.

The most recent analyst rating on (IGMS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on IGM Biosciences stock, see the IGMS Stock Forecast page.

Spark’s Take on IGMS Stock

According to Spark, TipRanks’ AI Analyst, IGMS is a Neutral.

IGM Biosciences’ overall stock score is low due to significant financial challenges and negative corporate events. While there is some technical momentum, valuation metrics are poor, and the company’s strategic difficulties pose ongoing risks.

To see Spark’s full report on IGMS stock, click here.

More about IGM Biosciences

IGM Biosciences, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies. The company primarily engages in creating and advancing targeted antibody treatments, aiming to address unmet medical needs in various disease areas.

Average Trading Volume: 180,073

Technical Sentiment Signal: Sell

Current Market Cap: $81.16M

See more insights into IGMS stock on TipRanks’ Stock Analysis page.